Heron Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Heron Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Heron Therapeutics Inc Strategy Report
- Understand Heron Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Heron Therapeutics Inc (Heron) is a biotechnology company that uses proprietary polymer-based drug delivery platform to develop novel, patient-focused drugs for patients suffering from various types of cancer and pain. Its proprietary Biochronomer technology is a polymer-based drug delivery platform, that improves the therapeutic profile of injectable pharmaceuticals. The company's marketed products include Sustol, an extended-release injection indicated in combination with other antiemetics in adults for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy (MEC); Cinvanti for chemotherapy-induced nausea and vomiting (CINV) prevention and Zynrelef (HTX-011) for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. Heron is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
4242 Campus Point Court, Suite 200, San Diego, California, 92121
Website
www.herontx.com
Telephone
1 858 2514400
No of Employees
126
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
HRTX (NASD)
Revenue (2022)
$127.0M
18%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
39.3%
(2022 vs 2021)
Market Cap*
$420.9M
Net Profit Margin (2022)
XYZ
48.5%
(2022 vs 2021)
* As of and is in US$
Heron Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| SustolL: | Cinvanti |
| Chemotherapy-Induced Nausea and Vomiting | Sustol |
| Acute and Delayed Nausea and Vomiting associated with Initial and Repeat Courses of Moderately Emetogenic Chemotherapy | Zynrelef |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In January, the company secured approval from the U.S. Food and Drug Administration for its supplemental New Drug Application for ZYNRELEF (bupivacaine and meloxicam) extended-release solution. |
| 2024 | Contracts/Agreements | In January, the company entered into a partnership with CrossLink Life Sciences to enlarge ZYNRELEF promotion for orthopedic indications. |
| 2023 | Regulatory Approval | In March, the company announced that CMS approved transitional pass-through status for APONVIE (aprepitant) injectable emulsion. |
Competitor Comparison
| Key Parameters | Heron Therapeutics Inc | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc | GSK plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | United Kingdom |
| City | San Diego | Basel | Kenilworth | New York | Brentford |
| State/Province | California | - | New Jersey | New York | England |
| No. of Employees | 126 | 103,605 | 72,000 | 88,000 | 70,212 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Adam Morgan | Chairman | Executive Board | 2023 | - |
| Craig Collard | Chief Executive Officer; Director | Executive Board | 2023 | - |
| Chris Storgard, M.D. | Chief Medical Officer | Senior Management | 2019 | 57 |
| Thomas B. Ottoboni, Ph.D. | Senior Vice President - Pharmaceutical and Translational Sciences; Chief Scientific Officer | Senior Management | 2019 | 64 |
| William Forbes | Executive Vice President; Chief Development Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward